SHRIPAL MAKIM: Open Payments
NPI 1104900141 · LAWRENCEVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,074 in 58 payments from 13 companies in 2025. Trend: 2023 $633 · 2024 $470 · 2025 $1,074
Food & beverage: $1,074
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 8 | $202 |
| ABBVIE INC. | 16 | $164 |
| Otsuka America Pharmaceutical, Inc. | 8 | $151 |
| Vanda Pharmaceuticals Inc. | 5 | $129 |
| Janssen Pharmaceuticals, Inc | 5 | $126 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
| E.R. Squibb & Sons, L.L.C. | 2 | $51 |
| Tris Pharma Inc | 2 | $51 |
| Corium, LLC | 3 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
Products named: INGREZZA, VRAYLAR, REXULTI, SPRAVATO, FANAPT, HETLIOZ, TRINTELLIX, COBENFY.
Industry payments across GA — which companies pay providers there.
